Related Experiment Videos
Vincristine neurotoxicity. Pathophysiology and management
Medical Toxicology
|November 1, 1986
Summary
Vincristine is an effective anticancer drug but can cause neurotoxicity, affecting nerves and muscles. This nerve damage is dose-dependent and usually reversible after treatment stops.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Vincristine is a widely used antineoplastic agent for various cancers.
- Unlike many chemotherapeutics, it has limited emetic and myelotoxic effects.
- Its clinical utility is significantly constrained by dose-limiting neurotoxicity.
Purpose of the Study:
- To detail the spectrum and characteristics of vincristine-induced neurotoxicity.
- To describe the clinical manifestations and progression of neurotoxic effects.
- To discuss the dose-dependency, reversibility, and management challenges of vincristine neurotoxicity.
Main Methods:
- Review of clinical data and pharmacological literature on vincristine.
- Analysis of reported cases detailing neurotoxic side effects.
- Correlation of dosage with observed neurotoxicity severity and type.
Main Results:
- Neurotoxicity presents as gastrointestinal motility reduction (constipation) and peripheral neuropathy (sensory and motor).
- Early signs include paresthesias and diminished reflexes; severe cases involve muscle weakness, particularly in distal extremities.
- Autonomic dysfunction (postural hypotension, bladder atony) and ocular palsies can also occur.
Conclusions:
- Vincristine neurotoxicity is cumulative and dose-related, necessitating treatment cessation at 30-50 mg cumulative doses.
- While generally reversible upon discontinuation, recovery is protracted, spanning several months.
- Currently, no specific antidotes demonstrate established efficacy against vincristine-induced neurotoxicity.